C Le Péchoux

Publications (2)12.32 Total impact

• Article: 1st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancer.

  R Stahel, N Thatcher, M Früh, C Le Péchoux, P E Postmus, J B Sorensen, E Felip
  [show abstract] [hide abstract]
  ABSTRACT: The 1st ESMO Consensus Conference on lung cancer was held in Lugano, Switzerland on 21st and 22nd May 2010 with the participation of a multidisciplinary panel of leading professionals in pathology and molecular diagnostics and medical, surgical and radiation oncology. Before the conference, the expert panel prepared clinically relevant questions concerning five areas as follows: early and locally advanced non-small-cell lung cancer (NSCLC), first-line metastatic NSCLC, second-/third-line NSCLC, NSCLC pathology and molecular testing, and small-cell lung cancer (SCLC) to be addressed through discussion at the Consensus Conference. All relevant scientific literature for each question was reviewed in advance. During the Consensus Conference, the panel developed recommendations for each specific question. The consensus agreement in SCLC is reported in this article. The recommendations detailed here are based on an expert consensus after careful review of published data. All participants have approved this final update.
  Annals of Oncology 07/2011; 22(9):1973-80. · 6.43 Impact Factor
• Article: Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma.

  A Scherpereel, P Astoul, P Baas, T Berghmans, H Clayson, P de Vuyst, H Dienemann, F Galateau-Salle, C Hennequin, G Hillerdal, C Le Péchoux, L Mutti, J-C Pairon, R Stahel, P van Houtte, J van Meerbeeck, D Waller, W Weder
  [show abstract] [hide abstract]
  ABSTRACT: Malignant pleural mesothelioma (MPM) is a rare tumour but with increasing incidence and a poor prognosis. In 2008, the European Respiratory Society/European Society of Thoracic Surgeons Task Force brought together experts to propose practical and up-to-dated guidelines on the management of MPM. To obtain an earlier and reliable diagnosis of MPM, the experts recommend performing thoracoscopy, except in cases of pre-operative contraindication or pleural symphysis. The standard staining procedures are insufficient in approximately 10% of cases. Therefore, we propose using specific immunohistochemistry markers on pleural biopsies. In the absence of a uniform, robust and validated staging system, we advice use of the most recent TNM based classification, and propose a three step pre-treatment assessment. Patient's performance status and histological subtype are currently the only prognostic factors of clinical importance in the management of MPM. Other potential parameters should be recorded at baseline and reported in clinical trials. MPM exhibits a high resistance to chemotherapy and only a few patients are candidates for radical surgery. New therapies and strategies have been reviewed. Because of limited data on the best combination treatment, we emphasise that patients who are considered candidates for a multimodal approach should be included in a prospective trial at a specialised centre.
  European Respiratory Journal 09/2009; 35(3):479-95. · 5.89 Impact Factor